Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Standard Biotools (LAB) over the last 17 years, with Q3 2025 value amounting to $129.4 million.

  • Standard Biotools' Cash & Equivalents fell 3893.59% to $129.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.4 million, marking a year-over-year decrease of 3893.59%. This contributed to the annual value of $166.7 million for FY2024, which is 21758.32% up from last year.
  • According to the latest figures from Q3 2025, Standard Biotools' Cash & Equivalents is $129.4 million, which was down 3893.59% from $158.6 million recorded in Q2 2025.
  • In the past 5 years, Standard Biotools' Cash & Equivalents registered a high of $288.3 million during Q1 2024, and its lowest value of $29.5 million during Q4 2021.
  • Moreover, its 5-year median value for Cash & Equivalents was $82.3 million (2022), whereas its average is $113.7 million.
  • Per our database at Business Quant, Standard Biotools' Cash & Equivalents crashed by 5866.28% in 2021 and then skyrocketed by 26923.13% in 2023.
  • Standard Biotools' Cash & Equivalents (Quarter) stood at $29.5 million in 2021, then soared by 179.38% to $82.3 million in 2022, then tumbled by 36.23% to $52.5 million in 2023, then soared by 217.58% to $166.7 million in 2024, then dropped by 22.38% to $129.4 million in 2025.
  • Its last three reported values are $129.4 million in Q3 2025, $158.6 million for Q2 2025, and $150.9 million during Q1 2025.